# List of Figures

1.1. Course of pancreatic cancer 3
1.2. Biomarker discovery pipeline 7
1.3. Selection of targets for the PDAC biomarker study 9
1.4. Experimental design of the PDAC biomarker study 18

2.1. Basics of tumor progression and metastasis 21
2.2. Strategies for biomarker discovery using emerging technologies 30

3.1. Overview of the Gateway cloning technology 37
3.2. Features of the destination vector 47
3.3. Agarose gel analysis of the PCR products (ORFs) 48
3.4. Agarose gel analysis of colony-PCR products (BP reaction for ITGB6) 49
3.5. Agarose gel analysis of colony-PCR products (LR reaction for ITGB6) 50
3.6. Western blot analysis of 293T whole cell lysates 52
3.7. Validation of protein expression by sandwich ELISA 53

4.1. Outline of the antibody production 58
4.2. a. Sequence and predicted structure of human LAD1 67
       b. Sequence homology of LAD1 between mouse and human species 68
       c. Peptides found for LAD1 by MS analysis of PDAC patient sera 69
       d. Hydropathy plot of full length LAD1 70
       e. Hydropathy plots of peptides selected for LAD1 71
4.3. Evaluation of anti-sera by indirect ELISA 74
4.4. Evaluation of anti-sera by Western blot assay 75
4.5. Hybridoma colony in HAT medium 77
4.6. Fusion screen by indirect ELISA 79
4.7. Western blot analysis of parental hybridomas 80
4.8. Early screening of hybridomas by rabbit-FLAG sandwich ELISA 82
4.9. Subclone screening by Western blot assay 85
4.10. Isotyping ELISA for antibody characterization 86
4.11. Antibody purifications

4.12. Evaluation of purified antibodies by Western blot and Immunoprecipitation

5.1. Outline of sandwich ELISA assay development
5.2. Sandwich ELISA development for LAD1
5.3. Verification of specificity for LAD1 ELISA by RNAi experiment
5.4. Evaluation of LAD1 expression in PDAC cell lines
5.5. Validation of LAD1 ELISA on serum samples
5.6. Development of sandwich ELISA assay for LAMB3
5.7. Determination of optimum capture-detection antibody combination for JUP (5.7a) and ITGB6 (5.7b) ELISA assays
5.8. Determination of specificities of JUP (5.9a) and ITGB6 (5.9b) ELISA assays
5.9. Evaluation of JUP and ITGB6 expression in PDAC cell lines
5.10. Serum evaluation of JUP (5.10a) and ITGB6 (5.10b) in control serum samples
5.11. Validation of DKK1 ELISA kit
5.12. Validation of CHI3L1 ELISA kit

6.1. Serum levels of LAD1, DKK1 and CHI3L1
6.2. Serum Expression of LAMB3, JUP and ITGB6